Physician profile
Scot G Fechtel
NPI 1881618569
$23,339.16
in general payments reported to CMS, 2019-2025
83 companies · $3,096 in 2025
The $3,096 reported for 2025 was more than what 94% of Neuromusculoskeletal Medicine, Sports Medicine providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,475 · 2020: $2,958 · 2021: $3,272 · 2022: $4,189 · 2023: $4,099 · 2024: $2,250 · 2025: $3,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,444.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,627.76 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $1,536.18 | 2019-2025 | |
| Abbvie INC. | $1,503.33 | 2019-2025 | |
| Lilly USA, LLC | $1,309.38 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Amgen INC. | $1,218.83 | 2019-2025 | Aimovig, Uplizna |
| Biogen, INC. | $1,111.51 | 2019-2025 | Vumerity, Tysabri |
| Allergan, INC. | $952.28 | 2019-2022 | |
| Genzyme Corporation | $887.01 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $867.98 | 2019-2025 | Ultomiris |
| Eisai INC. | $764.38 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $748.96 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genentech USA, INC. | $730.82 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Pfizer INC. | $630.72 | 2019-2025 | |
| Argenx US, INC. | $603.22 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Upsher-Smith Laboratories LLC | $538.83 | 2019-2023 |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scot Fechtel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.